Wang X, et al. - Researchers estimated 85 locally high-risk prostate cancer (PCa) patients with matched preoperative needle biopsies to assess pathological variables that can forecast differences in neoadjuvant hormonal therapy (NHT) response in PCa using a new proposed pathological grading system. They characterized the PCa cases into a drug-sensitive group (Grades 2-4) and a drug-resistant group (Grades 0-1). They observed 4 pathological variables (ie, cribriform growth pattern, macronucleoli, ductal adenocarcinoma differentiation, and PTEN loss) that were correlated with tumor response to NHT. They suggested better performance was seen with combined pathological indicators in predicting response vs that of a model based on one factor alone.